Randomized Phase II Study of Stereotactic Body Radiotherapy + Anti-PD1 Antibody (Pembrolizumab) in Advanced Merkel Cell Carcinoma

Trial Profile

Randomized Phase II Study of Stereotactic Body Radiotherapy + Anti-PD1 Antibody (Pembrolizumab) in Advanced Merkel Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top